Business
Altimmune Announces First Quarter 2025 Financial Results and Business Update
Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD), expected to initiate in Q2 and Q3 2025, respectively Cash, cash equivalents and short-term investments of $150 million as of March 31, 2025 $100 million credit facility secured with Hercules Capital, adding balance sheet strength and financial flexibility to support continued developmen
About this update from Altimmune, Inc.
[{"type":"image","alt":"Altimmune, Inc","displaySize":"","headline":null,"caption":"Altimmune, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":82,"url":"https://media.zenfs.com/en/globenewswire.com/767e25bad8979b96701d6a099286a009"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gY.Kxe7ML79dI0xW5370RA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/767e25bad8979b96701d6a099286a009","width":150,"height":82}},"lazy":false},{"type":"text","content":"Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025","length":134,"tagName":"p"},{"type":"text","content":"Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD), expected to initiate in Q2 and Q3 2025, respectively","length":130,"tagName":"p"},{"type":"text","content":"Cash, cash equivalents and short-term investments of $150 million as of March 31, 2025 ","length":86,"tagName":"p"},{"type":"text","content":"$100 million credit facility secured with Hercules Capital, adding balance sheet strength and financial flexibility to support continued development of pemvidutide","length":163,"tagName":"p"},{"type":"text","content":"Webcast to be held today, May 13, 2025, at 8:30 a.m. ET","length":55,"tagName":"p"},{"type":"text","content":"GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.","length":324,"tagName":"p"},{"type":"text","content":"“The first quarter of 2025 was productive for Altimmune as the Company approaches a number of important milestones,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “The readout of our IMPACT Phase 2b trial of pemvidutide in MASH is on-track for the second quarter of 2025. We believe that achieving statistical significance on MASH resolution and fibrosis improvement at only 24 weeks, coupled with clinically meaningful weight loss, would position pemvidutide as the best-in-class therapeutic candidate for the treatment of MASH.”","length":563,"tagName":"p"},{"type":"text","content":"Dr. Ga...